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Introduction
Multiple myeloma (MM), the malignant disorder of antibody producing clonal plasma cells is the second most common hematologic neoplasia worldwide. 1 Despite four decades of drug innovation, MM remains incurable with chemotherapy. Furthermore, the prognosis of MM patients, who become refractory to recently developed novel agents, is very poor. 2 On the other hand, clinical and experimental data collected over the past decades suggest the possibility to successfully treat MM through (cellular) immunotherapy. 3, 4 The curative potential of cellular immunotherapy in MM is illustrated by the induction of long-term sustained remissions after allogeneic stem cell transplantation (SCT) or donor lymphocyte infusions (DLI) in a subset of patients. 5, 6 A highly appealing and more specific immunotherapy strategy for cancer is the adoptive transfer of cytotoxic T cells (CTLs) that are genetically engineered to express Chimeric Antigen Receptors (CAR). 7, 8 A CAR is an artificial hybrid receptor, in which the antigen recognizing domain of a tumor-reactive monoclonal antibody is fused with T-cell signaling domains. Upon retro-or lentiviral transduction of CTLs, CARs expressed on the cell surface redirect the CTLs toward the original target of the antibody in a non-HLA restricted manner 7, 8 , providing the possibility to apply the therapy regardless of the HLA type of the patient. Currently the most successful CAR-approaches are based on targeting the CD19 molecule, which is broadly expressed in several B cell malignancies but not on malignant plasma cells of MM patients. Among a few potential CAR candidates for MM 9 , the CD38 molecule, with its high and uniform expression on malignant plasma cells, has long been suggested a suitable target for antibody therapy of MM. The utility of CD38 as a suitable target has indeed been supported by the results of recently initiated clinical trials in which MM patients were safely and effectively treated with the CD38-specific human monoclonal antibody daratumumab 10 .
Encouraged by these clinical results, we now started to explore the feasibility of development of a CART cell therapy based on targeting the CD38 molecule. Using variable heavy and light chain sequences of three different human CD38 antibodies, we generated Haematologica HAEMATOL/2015/137620 Version 3 5 three different CD38-CARs. We transduced T cells from healthy individuals and MM patients with CD38-CARs and evaluated them for essential functions such as antigenspecific proliferation and cytokine production, for in vitro and in vivo anti-tumor efficacy and for potential undesired effects such as targeting normal CD38 + cell fractions in the peripheral blood and bone marrow. We also evaluated the feasibility of controlling CD38-CART cells by introduction of a caspase-9 based suicide gene.
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Methods

Bone marrow Mononuclear cells (BM-MNC) from MM and AML patients
Bone marrow mononuclear cells containing 5-20% malignant plasma cells or ~50% AML blasts were isolated from bone marrow aspirates of MM/AML patients through Ficoll-Paque density centrifugation and cryopreserved in liquid nitrogen until use. All bone marrow and blood sampling from the patients was performed after informed consent and approved by the institutional medical ethical committee.
PBMC from healthy individuals
PBMCs were isolated from Buffy coats of healthy blood-bank donors by Ficoll-Paque density centrifugation after informed consent and approval by the institutional medical ethical committee.
Retroviral constructs
The sequences of three different human CD38 antibodies, which are distinct from, but display similar affinities to the recently documented daratumumab 10 (Table S1) were kindly provided by Genmab. Cloning methods are described in supplementary methods.
Retroviral CAR Transduction into T cells
Transduction methods are described in supplementary methods.
Flow cytometry-based cell lysis assays
To detect the lysis of various cell subsets by CART cells in whole BMNC or in PBMC, serial dilutions of CART cells were incubated with CFSE labeled BMMNC or PBMC for 24 hours. 
BLI-based cell lysis assays
To determine the lysis of Luc-GFP-transduced human malignant cell lines by CD38-CART cells, serial dilutions of mock or CD38-CART cells were co-incubated with the malignant cell lines. The luciferase signal produced by surviving malignant cells was determined after 16-24 hours with a luminometer SpectraMax, Molecular Devices within 15 minutes after the addition of 125 μ g/mL beetle luciferin (Promega). 11 The percent lysis was then calculated as in flow-based cytotoxicity assay above.
Experimental animals
RAG2
-/-γ c -/-mice used in this study were originally obtained from the Amsterdam Medical
Center (AMC, Amsterdam, the Netherlands). The mice were bred and maintained in filter top cages under specified pathogen-free conditions at the Central Animal Facility (GDL, Utrecht University, Utrecht, the Netherlands) and received sterile water and radiationsterilized food pellets ad libitum.
In vivo efficacy of CD38-CART cells against MM tumors growing in a humanized microenvironment.
To create a human bone marrow-like environment in mice, hybrid scaffolds were coated in vitro with human mesenchymal stromal cells. After a week of in vitro culture, humanized scaffolds were seeded with CD38 + UM9 cells and implanted subcutaneously into the mice, as described previously, 11,12 and described in supplementary methods.
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Results
Generation of CD38-CART cells
We used the variable heavy and light chain sequences of three different CD38 antibodies with CD38 binding affinities comparable to daratumumab (Table S1) , which is now being 
CD38-dependent proliferation and cytokine secretion of CD38-CART cells.
To analyze the proliferative and functional properties, the neomycin-selected, highly purified CD38-CART cells were expanded using irradiated feeder cells in the presence of PHA and 
CD38-dependent lysis of MM cell lines by CD38-CART cells
To determine the CD38-dependent lysis of malignant cells by CD38-CART cells, we first used luciferase-transduced MM cell lines with variable CD38 expression levels in BLI-based cytotoxicity assays. 11,14 As expected, there was no CD38-CAR-specific lysis of the CD38 -U266 cell line ( Fig. 2A) . In contrast, all three CD38-CART cells, but not mock-T cells, effectively lysed CD38 + MM cell line UM9 in a cell-dose dependent manner ( 
Lysis of primary MM and AML cells by CD38-CART cells.
To test the efficacy of CD38-CART cells against primary MM and AML cells, we used a previously described flow cytometry-based ex vivo cytotoxicity assay, in which the lysis of malignant cells is tested, directly in the BM-MNCs without isolating them from other cells. 15 As depicted in Figure 3A CD38 (patient 2) were effectively lysed by CD38-CART cells ( Fig 3A) . Finally, CD38-CART cells that were generated ( Fig 3B) from a MM patient were effective towards autologous malignant MM cells in BM-MNCs indicating the feasibility of generating effective CD38CART cells also from MM patients.
Fully-functional CD38 CART cells are negative for CD38
While CD38-CART cells had no apparent functional deficiencies, a phenotyping assay revealed that they, despite a mixed effector/central memory phenotype, lost the expression of CD38 (Fig. 4A ). Interestingly, when we co-cultured CD38-CART cells with an autologous CD19 CART cell population, these CD19CART cells also became largely negative for CD38
expression but fully maintained their capacities to proliferate, secrete cytokines and kill the relevant target cells in a CD19 dependent fashion (supplementary Figure S2 ), indicating that the loss of CD38 was not associated with detectable T cell dysfunction. Nonetheless, since CD38 molecule could also play a role in migration, we also evaluated whether CD38 negative CD38-CART cells would properly migrate through endothelial layers in a transwell migration assay ( fig 4B) . These assays revealed no differences between the mocktransduced, CD38-positive and CD38-CAR-transduced CD38-negative T cells, ruling out an apparent migratory dysfunction of CD38-CART cells.
In vivo efficacy of CD38-CART cells against MM tumors growing in a humanized microenvironment.
To substantiate the in vitro results, we questioned whether the CD38 negative CART cells were still positive for CD38 (Fig. 4D) , thus ruling out tumor escape due to "antigen loss"
variants. colony forming assay 18, 19 ( Fig. 5C and D) .
Impact of CD38-CART cells on CD38
Specific elimination of CD38-CART cells using a suicide gene (iCasp9)
Although CD38-CART cells did not lyse the CD38 negative fractions of mature hematopoietic cells and did not inhibit the outgrowth of these cell populations, still a cautious approach toward the clinical application is required. Therefore, as a first step towards a more safe application of CD38-CART cells, we tested the possibility to control transduced, GFP+ but none of the iCasp9 non-transduced, GFP-CD38-CART cells were eliminated upon incubation with the dimerizer AP20187 ( Fig. 6A lower panel) . As expected, the dimerizer treatment also resulted in a proportional decrease in the lysis of the MM cell line UM9. (Fig. 6B) . There was still a remaining lysis due to the surviving iCasp9 negative CD38-CART cells, indicating that the triggering of suicide gene induced no bystander damage to the cells in the close vicinity. When tested after sorting of GFP+ cells (Fig 6C   and 6D ), almost all GFP+ cells died after treatment with the dimerizer (Fig. 6C) and there was no CD38 specific lysis left (Fig 6D) , confirming the results obtained by previous studies 20, 21 , and suggesting the possibility to control CD38-CART cells using the iCasp9 suicide gene without undesired consequences.
Haematologica HAEMATOL/2015/137620 Version 3 expression on their surface in various independently generated batches of cells. The loss of CD38 was thus unlikely to be caused by a genetic defect, but was most probably due to the "self lysis" of the CD38 + fractions, which was also described in another CD38-CAR study 29 .
Our CD38 negative CD38-CART cells, however, had no growth disadvantage, displayed highly activated status, CD38-dependent proliferation, cytokine production, cytotoxic activities and showed no other detectable functional aberrancies. This was also the case for CD19CART cells which became CD38 negative after co-culture with CD38-CART cells ( Figure S2 ). Furthermore CD38-CART cells did not show any defects in a transmigration assays and they also mediated significant anti-MM effects in vivo, thus indicating their capacity to properly migrate and infiltrate into the MM niches and to kill them. Thus, it seems likely that i) not all activated T cells have to be CD38 positive and ii) CD38 expression is not essential for T cells to fulfill their functions. This conclusion is also supported by the fact that there is yet no evidence, even in CD38 KO mice, 32 that CD38-deficient effector T cells are defective in function.
On the other hand, the relative broad expression of the target antigen of CD38-CART cells increases the risk of the so called "cytokine release syndrome (CRS)" due to massive activation of CAR-T cells, as have been observed in the previous trials with ERBB2-and CD19-CART cells. [35] [36] [37] Although the IL-6R antagonist tocilizumab appears to successfully reduce CRS 38 it would still be desirable to minimize the occurrence of such severe side effects. Furthermore, since we cannot rule out toxicities occurring die to the possible attack of non-hematopoietic CD38 + cells, development of an optimal CD38-CART cell therapy 1 6 would require the improvement of the target-specificity as well as the in vivo control on 43, 44 , and CD44v6. 45 Haematologica HAEMATOL/2015/137620 Version 3
